Although treatment with LUM led to partial response and stable disease, notably in patients with non-small cell lung cancer (NSCLC) with mutations in EGFR and ALK21, it failed to meet clinical trial endpoints, and its systemic administration resulted in a high occurrence of ophthalmological toxicities hindering further development10,25–28. This evidence concerns the gene EGFR and non-small cell lung carcinoma.